Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma

Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2017-07, Vol.52 (7), p.969-976
Hauptverfasser:	Yamasaki, S, Suzuki, R, Hatano, K, Fukushima, K, Iida, H, Morishima, S, Suehiro, Y, Fukuda, T, Uchida, N, Uchiyama, H, Ikeda, H, Yokota, A, Tsukasaki, K, Yamaguchi, H, Kuroda, J, Nakamae, H, Adachi, Y, Matsuoka, K-i, Nakamura, Y, Atsuta, Y, Suzumiya, J
Format:	Artikel
Sprache:	eng
Schlagworte:	692/499 692/699/1541/1990/283/1897 692/700/565/2319 Acute myeloid leukemia Adolescent Adult Aged Aged, 80 and over Allografts Autografts Care and treatment Cell Biology Cord blood FDA approval Female Follow-Up Studies Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Incidence Internal Medicine Leukemia Leukemia, Myeloid, Acute - epidemiology Lymphoma Lymphoma - epidemiology Lymphoma - therapy Male Medicine Medicine & Public Health Middle Aged Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - epidemiology Myeloid leukemia Neoplasms, Second Primary - epidemiology original-article Patients Public Health Radiation therapy Radiotherapy Risk analysis Risk Factors Stem cell transplantation Stem Cells Transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-AML/MDS) represent severe late effects in patients receiving hematopoietic cell transplantation (HCT) for lymphoma. The choice between high-dose therapy with autologous HCT and allogeneic HCT with reduced-intensity conditioning remains controversial in patients with relapsed lymphoma. We retrospectively analyzed incidence and risk factors for the development of t-AML/MDS in lymphoma patients treated with autologous or allogeneic HCT. A total of 13 810 lymphoma patients who received autologous ( n =9963) or allogeneic ( n =3847) HCT between 1985 and 2012 were considered. At a median overall survival (OS) of 52 and 46 months in autologous and allogeneic HCT groups, respectively, lymphoma patients receiving autologous HCT (1.38% at 3 years after autologous HCT) had a significant risk for developing t-AML/MDS compared to allogeneic HCT (0.37% at 3 years after allogeneic HCT, P
ISSN:	0268-3369 1476-5365
DOI:	10.1038/bmt.2017.52